Loading

Journal of Clinical Nephrology and Research

How to Prevent ContrastInduced Nephropathy in Clinical Practice

Review Article | Open Access | Volume 1 | Issue 1

  • 1. Department of Health Sciences, Magna Graecia University, Italy
  • 2. Department of Public Health, Federico II University, Italy
+ Show More - Show Less
Corresponding Authors
Michele Andreucci, Department of Health Sciences, Magna Graecia University, Nephrology Unit, Campus Salvatore Venuta, Viale Europa, loc. Germaneto, I-88100 Catanzaro, Italy
Abstract

After the description of the Contrast-Induced Nephropathy (CIN), its epidemiology and its pathogenesis, the risk factors for the development of CIN are discussed in depth, the main ones being pre-existing renal impairment, particularly secondary to diabetic nephropathy, salt depletion and dehydration, congestive heart failure, age greater than 70 years and concurrent use of nephrotoxic drugs. Then the measures to prevent CIN are suggested, beginning with the main rules in prevention: monitoring renal function, discontinuation of potentially nephrotoxic drugs, use of either iodixanol, an iso-osmolar contrast medium or iopamidol, a low-osmolar contrast medium at the lowest dosage possible. The main procedure for prevention of CIN is an adequate hydration of the patient with either isotonic sodium chloride or sodium bicarbonate solutions. The antioxidant N-acetylcysteine may be added orally or intravenously. Other antioxidants, such as vitamin C (ascorbic acid) and vitamin E (a- or γ-tocopherol), compounds with antioxidant properties (e.g. Mesna), and β1-adrenergic receptor antagonists (e.g. Nebivolol) require further studies before deciding their use in clinical practice to prevent CIN.
 

REFERENCES

1. Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010; 256: 21-28.

2. Andreucci M, Solomon R, Tasanarong A. Side Effects of Radiographic Contrast Media: Pathogenesis, Risk Factors, and Prevention. Biomed Res Int. 2014; 2014: 741018.

3. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003; 76: 513-518.

4. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006; : S11-15.

5. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of internal medicine. 1999; 130: 461-470.

6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.

7. Solomon R. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clin J Am Soc Nephrol. 2008; 3: 1242-1243.

8. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. Journal of the American College of Cardiology. 1999; 33: 1756-1824.

9. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997; 103: 368-375.

10. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol. 2004; 183: 1673-1689.

11. Andreucci VE, Fuiano G, Russo D, Andreucci M. Vasomotor nephropathy in the elderly. Nephrol Dial Transplant. 1998; 13 Suppl 7: 17-24.

12. Andreucci VE, Fuiano G, Stanziale P, Andreucci M. Role of renal biopsy in the diagnosis and prognosis of acute renal failure. Kidney Int Suppl. 1998; 66: S91-95.

13. Davenport MS, Khalatbari S, Cohan RH, Dillman JR, Myles JD, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology. 2013; 268: 719-728.

14. Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH. Contrast material-induced nephrotoxicity and intravenous lowosmolality iodinated contrast material. Radiology. 2013; 267: 94-105.

15. McDonald RJ, McDonald JS, Bida JP, Carter RE, Fleming CJ, Misra S, et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology. 2013; 267: 106-118.

16. McDonald JS, McDonald RJ, Comin J, Williamson EE, Katzberg RW, Murad MH, et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology. 2013; 267: 119-128.

17. Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol. 2009; 4: 1162-1169.

18. Andreucci M, Faga T, Pisani A, Sabbatini M, Michael A. Acute Kidney Injury by Radiographic Contrast Media: Pathogenesis and Prevention. BioMed Research Int. in press. 2014.

19. Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev. 2004; 18: 2183-2194.

20. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000; 11: 177-182.

21. Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol. 2010; 45: 188-195.

22. Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant. 2005; 20: 1542-1550.

23. Pisani A, Riccio E, Andreucci M, Faga T, Michael A, Di Nuzzi A, et al. Role of reactive oxygen species (ROS) in pathogenesis of RadiocontrastInduced Nephropathy. Andreucci M, Solomon R, Tasanarong A, editors. In: “Side Effects of Radiographic Contrast Media”. Special Issue. Biomed Res Int. 2013.

24. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol. 2008; 3: 281-287.

25. Myers SI, Wang L, Liu F, Bartula LL. Iodinated contrast induced renal vasoconstriction is due in part to the downregulation of renal cortical and medullary nitric oxide synthesis. J Vasc Surg. 2006; 44: 383-391.

26. Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB. Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology. 2009; 251: 697-704.

27. Pisani A, Sabbatini M, Riccio E, Rossano R, Andreucci M, Capasso C, et al. Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. Clinical and experimental nephrology. 2013.

28. Sendeski MM. Pathophysiology of renal tissue damage by iodinated contrast media. Clin Exp Pharmacol Physiol. 2011; 38: 292-299.

29. Hardiek K, Katholi RE, Ramkumar V, Deitrick C. Proximal tubule cell response to radiographic contrast media. Am J Physiol Renal Physiol. 2001; 280: F61-70.

30. Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology. 2005; 235: 843-849.

31. Andreucci M, Lucisano G, Faga T, Bertucci B, Tamburrini O, Pisani A, et al. Differential activation of signaling pathways involved in cell death, survival and inflammation by radiocontrast media in human renal proximal tubular cells. Toxicol Sci. 2011; 119: 408-416.

32. Michele Andreucci, Giorgio Fuiano, Pierangela Presta, Pasquale Esposito, Teresa Faga, Vincenzo Bisesti, et al. Radio contrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells. Biochem Pharmacol. 2006; 72: 1334-1342.

33. Andreucci M, Faga T, Russo D, Bertucci B, Tamburrini O, Pisani A, et al. Differential activation of signaling pathways by low-osmolar and isoosmolar radiocontrast agents in human renal tubular cells. Journal of cellular biochemistry. 2014; 115: 281-289.

34. Michael A, Faga T, Pisani A, Riccio E, Bramanti P, Sabbatini M, et al. Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media. Andreucci M, Solomon R, Tasanarong A, editors. In: “Side Effects of Radiographic Contrast Media”. Special Issue. BioMed Research Int. 2014.

35. Andreucci M. [Contrast media and nephrotoxicity: a molecular conundrum]. G Ital Nefrol. 2011; 28: 355.

36. Sabbatini M, Santillo M, Pisani A, Paternò R, Uccello F, Serù R, et al. Inhibition of Ras/ERK1/2 signaling protects against postischemic renal injury. American journal of physiology Renal physiology. 2006; 290: F1408-1415.

37. Andreucci M, Faga T, Lucisano G, Uccello F, Pisani A, Memoli B, Sabbatini M. Mycophenolic acid inhibits the phosphorylation of NFkappaB and JNKs and causes a decrease in IL-8 release in H2O2- treated human renal proximal tubular cells. Chem Biol Interact. 2010; 185: 253-262.

38. Andreucci M, Michael A, Kramers C, Park KM, Chen A, Matthaeus T, Alessandrini A. Renal ischemia/reperfusion and ATP depletion/ repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHRL1. Kidney Int. 2003; 64: 1189-1198.

39. Andreucci M, Fuiano G, Presta P, Lucisano G, Leone F, Fuiano L, et al. Down regulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. Cell Prolif. 2009; 42: 554-561.

40. Persson PB, Hansell P, Liss P. Pathophysiology of contrast mediuminduced nephropathy. Kidney Int. 2005; 68: 14-22.

41. Singh J, Daftary A. Iodinated contrast media and their adverse reactions. J Nucl Med Technol. 2008; 36: 69-74.

42. Cunha MA, Schor N. Effects of gentamicin, lipopolysaccharide, and contrast media on immortalized proximal tubular cells. Renal failure. 2002; 24: 687-690.

43. Peer A, Averbukh Z, Berman S, Modai D, Averbukh M, Weissgarten J. Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells. Investigative radiology. 2003; 38: 177-182.

44. Haller C, Hizoh I. The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol. 2004; 39: 149-154.

45. McCullough PA. Acute kidney injury with iodinated contrast. Crit Care Med. 2008; 36: S204-211.

46. Weisbord SD. Iodinated contrast media and the kidney. Rev Cardiovasc Med. 2008; 9 Suppl 1: S14-23.

47. Osthoff M, Katan M, Fluri F, Schuetz P, Bingisser R, Kappos L, et al. Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One. 2011; 6: e21338.

48. Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. European heart journal. 2010; 31: 1181-1187.

49. Osthoff M, Trendelenburg M. Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction. Andreucci M, Solomon R, Tasanarong A, editors. In: Side Effects of Radiographic Contrast Media. BioMed research international. 2013; 2013: 962695.

50. van der Pol P, Schlagwein N, van Gijlswijk DJ, Berger SP, Roos A, Bajema IM, et al. Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am J Transplant. 2012; 12: 877-887.

51. Gorsuch WB, Chrysanthou E, Schwaeble WJ, Stahl GL. The complement system in ischemia-reperfusion injuries. Immunobiology. 2012; 217: 1026-1033.

52. de Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heurn LW, Buurman WA. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol. 2004; 165: 1677-1688.

53. Wang L, Ni Z, Xie Z, Yang F, He B, Liu J, et al. Analysis of the urine proteome of human contrast-induced kidney injury using two-dimensional fluorescence differential gel electrophoresis/matrix---assisted laser desorption time-of-flight mass spectrometry/liquid chromatography mass spectrometry. American journal of nephrology. 2010; 31: 45-52.

54. Osthoff M, Piezzi V, Klima T, Christ A, Marana I, Hartwiger S, et al. Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial. BMC Nephrol. 2012; 13: 99.

55. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002; 40: 221-226.

56. Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004; 66: 1115-1122.

57. Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H,  et al. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol. 2004; 61: 98-102.

58. Kimmel M, Butscheid M, Brenner S, Kuhlmann U, Klotz U, Alscher DM. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results. Nephrol Dial Transplant. 2008; 23: 1241- 1245.

59. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999; 9: 1602-1613.

60. Hardiek KJ, Katholi RE, Robbs RS, Katholi CE. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabetes Complications. 2008; 22: 171-177.

61. Pakfetrat M, Nikoo MH, Malekmakan L, Tabande M, Roozbeh J, Ganbar Ali RJ, et al. Comparison of risk factors for contrast-induced acute kidney injury between patients with and without diabetes. Hemodial Int. 2010; 14: 387-392.

62. Morabito S, Pistolesi V, Benedetti G, Di Roma A, Colantonio R, Mancone M, et al. Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography. J Nephrol. 2012; 25: 1098-1107.

63. Rudnick MR, Goldfarb S, Tumlin J. Contrast-induced nephropathy: is the picture any clearer? Clin J Am Soc Nephrol. 2008; 3: 261-262.

64. Morcos SK. Contrast media-induced nephrotoxicity--questions and answers. Br J Radiol. 1998; 71: 357-365.

65. Kolonko A, Kokot F, Wiecek A. Contrast-associated nephropathy-- old clinical problem and new therapeutic perspectives. Nephrol Dial Transplant. 1998; 13: 803-806.

66. Toprak O. Conflicting and new risk factors for contrast induced nephropathy. J Urol. 2007; 178: 2277-2283.

67. Neyra JA, Shah S, Mooney R, Jacobsen G, Yee J, Novak JE. Contrastinduced acute kidney injury following coronary angiography: a cohort study of hospitalized patients with or without chronic kidney disease. Nephrol Dial Transplant. 2013; 28: 1463-1471.

68. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, ; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001; 104: 1985-1991.

69. Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrastinduced nephropathy. Nephron Clin Pract. 2006; 104: c20-27.

70. Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H. Impact of reninangiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol Dial Transplant. 2010; 25: 759-764.

71. Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, et al. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study. Am J Kidney Dis. 2012; 60: 576-582.

72. Umruddin Z, Moe K, Superdock K. ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy. J Nephrol. 2012; 25: 776-781.

73. Onuigbo MA, Onuigbo NT. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study. Renal failure. 2008; 30: 67-72.

74. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. 2008; 40: 749-755.

75. Khwaja A. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international. 2012; 2: 1-138.

76. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med. 1994; 331: 1449-1450.

77. Andreucci M, Federico S, Andreucci VE. Edema and acute renal failure. Semin Nephrol. 2001; 21: 251-256.

78. Andreucci VE, Russo D, Cianciaruso B, Andreucci M. Some sodium, potassium and water changes in the elderly and their treatment. Nephrol Dial Transplant. 1996; 11: 9-17.

79. Bartels ED, Brun GC, Gammeltoft A, Gjørup PA. Acute anuria following intravenous pyelography in a patient with myelomatosis. Acta Med Scand. 1954; 150: 297-302.

80. Pahade JK, LeBedis CA, Raptopoulos VD, Avigan DE, Yam CS, Kruskal JB, et al. Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT. AJR Am J Roentgenol. 2011; 196: 1094-1101.

81. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol. 1983; 141: 1027-1033.

82. Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney international. 2005; 67: 706-713.

83. Ahuja TS, Niaz N, Agraharkar M. Contrast-induced nephrotoxicity in renal allograft recipients. Clin Nephrol. 2000; 54: 11-14.

84. Oliveira DB. Prophylaxis against contrast-induced nephropathy. Lancet. 1999; 353: 1638-1639.

85. Taliercio CP, Vlietstra RE, Fisher LD, Burnett JC. Risks for renal dysfunction with cardiac angiography. Ann Intern Med. 1986; 104: 501-504.

86. McCullough P. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv. 2006; 67: 335-343.

87. Kato K, Sato N, Yamamoto T, Iwasaki YK, Tanaka K, Mizuno K. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circ J. 2008; 72: 1499-1505.

88. Nunag M, Brogan M, Garrick R. Mitigating contrast-induced acute kidney injury associated with cardiac catheterization. Cardiol Rev. 2009; 17: 263-269.

89. Dong M, Jiao Z, Liu T, Guo F, Li G. Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials. J Nephrol. 2012; 25: 290-301.

90. Byrd L, Sherman RL. Radiocontrast-induced acute renal failure: a clinical and pathophysiologic review. Medicine (Baltimore). 1979; 58: 270-279.

91. Harkonen S, Kjellstrand C. Contrast nephropathy. Am J Nephrol. 1981; 1: 69-77.

92. Khoury GA, Hopper JC, Varghese Z, Farrington K, Dick R, Irving JD, et al. Nephrotoxicity of ionic and non-ionic contrast material in digital vascular imaging and selective renal arteriography. Br J Radiol. 1983; 56: 631-635.

93. Moore RD, Steinberg EP, Powe NR, Brinker JA, Fishman EK, Graziano S, et al. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology. 1992; 182: 649-655.

94. Katzberg RW, Barrett BJ. Risk of iodinated contrast material--induced nephropathy with intravenous administration. Radiology. 2007; 243: 622-628.

95. Campbell DR, Flemming BK, Mason WF, Jackson SA, Hirsch DJ, MacDonald KJ. A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography. Can Assoc Radiol J. 1990; 41: 133-137.

96. Gomes AS, Baker JD, Martin-Paredero V, Dixon SM, Takiff H, Machleder HI, et al. Acute renal dysfunction after major arteriography. AJR Am J Roentgenol. 1985; 145: 1249-1253.

97. Bucher AM, De Cecco CN, Schoepf UJ, Meinel FG, Krazinski AW, Spearman JV, et al. Is contrast medium osmolality a causal factor for contrast-induced nephropathy? Andreucci M, Solomon R, Tasanarong A, editors. In: “Side Effects of Radiographic Contrast Media”. Special Issue. BioMed Research Int. 2014.

98. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and LowOsmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003; 348: 491-499.

99. Taliercio CP, Vlietstra RE, Ilstrup DM, Burnett JC, Menke KK, Stensrud SL, et al. A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol. 1991; 17: 384-390.

100. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993; 188: 171-178.

101. Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol. 1994; 5: 125- 137.

102. Heinrich MC, Häberle L, Müller V, Bautz W, Uder M. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology. 2009; 250: 68-86.

103. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007; 115: 3189-3196.

104. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovascular interventions. 2009; 2: 645-654.

105. Bolognese L, Falsini G, Schwenke C, Grotti S, Limbruno U, Liistro F, et al. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial). Am J Cardiol. 2012; 109: 67-74.

106. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol. 1999; 72: 701-703.

107. Ad-hoc working group of ERBP, Fliser D, Laville M, Covic A, Fouque D, Vanholder R, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012; 27: 4263-4272.

108. Thomson K. Safe use of radiographic contrast media. Aust Prescr. 2010; 33: 19-22.

109. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989; 86: 649-652.

110. Laskey WK, Jenkins C, Selzer F, Marroquin OC, Wilensky RL, Glaser R, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007; 50: 584-590.

111. Keaney JJ, Hannon CM, Murray PT. Contrast-induced acute kidney injury: how much contrast is safe? Nephrol Dial Transplant. 2013; 28: 1376-1383.

112. Gurm HS, Dixon SR, Smith DE, Share D, Lalonde T, Greenbaum A, et al. Registry. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011; 58: 907-914.

113. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int Suppl. 2006; : S16-19.

114. Balemans CE, Reichert LJ, van Schelven BI, van den Brand JA, Wetzels JF. Epidemiology of contrast material-induced nephropathy in the era of hydration. Radiology. 2012; 263: 706-713.

115. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol. 2003; 181: 1463-1471.

116. Ellis JH, Cohan RH. Prevention of contrast-induced nephropathy: an overview. Radiol Clin North Am. 2009; 47: 801-81, v.

117. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation. 2010; 122: 2451-2455.

118. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004; 291: 2328- 2334.

119. Masuda M, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol. 2007; 100: 781-786.

120. Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007; 154: 539-544.

121. Tamura A, Goto Y, Miyamoto K, Naono S, Kawano Y, Kotoku M, et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol. 2009; 104: 921-925.

122. Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009; 53: 617-627.

123. Hoste EA, De Waele JJ, Gevaert SA, Uchino S, Kellum JA. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant. 2010; 25: 747-758.

124. Joannidis M, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr. 2008; 120: 742-748.

125. Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. Pediatr Cardiol. 2006; 27: 238-242.

126. Pakfetrat M, Nikoo MH, Malekmakan L, Tabandeh M, Roozbeh J, Nasab MH, et al. A comparison of sodium bicarbonate infusion versus normal saline infusion and its combination with oral acetazolamide for prevention of contrast-induced nephropathy: a randomized, double-blind trial. Int Urol Nephrol. 2009; 41: 629-634.

127. Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim TH, Urm SH. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury – a systematic review and meta-analysis –. Circ J. 2012; 76: 2255-2265.

128. Reddan D, Laville M, Garovic VD. Contrast-induced nephropathy and its prevention: What do we really know from evidence-based findings? J Nephrol. 2009; 22: 333-351.

129. Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Annals of internal medicine. 2009; 151: 631-638.

130. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008; 300: 1038- 1046.

131. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4: 1584-1592.

132. Shavit L, Korenfeld R, Lifschitz M, Butnaru A, Slotki I. Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. J Interv Cardiol. 2009; 22: 556-563.

133. Vasheghani-Farahani A, Sadigh G, Kassaian SE, Khatami SM, Fotouhi A, Razavi SA, et al. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009; 54: 610-618.

134. From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic. Clin J Am Soc Nephrol. 2008; 3: 10-18.

135. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents--a new use for an old drug. N Engl J Med. 2000; 343: 210-212.

136. Lee HC, Sheu SH, Liu IH, Lee CC, Hsieh CC, Yen HW, et al. Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. J Nephrol. 2012; 25: 56-62.

137. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetyl cysteine ameliorates ischemic renal failure. Am J Physiol. 1997; 272: F292-298.

138. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000; 343: 180-184.

139. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003; 41: 2114-2118.

140. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004; 25: 206- 211.

141. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002; 62: 2202-2207.

142. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002; 57: 279-283.

143. Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004; 25: 212-218.

144. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004; 65: 1366-1374.

145. Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J. 2006; 151: 1032.

146. Ferrario F, Barone MT, Landoni G, Genderini A, Heidemperger M, Trezzi M, et al. Piccaluga, P. Danna, and D. Scorza. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study. Nephrology, dialysis, transplantation. 2009; 24: 3103-3107.

147. Gurm HS, Smith DE, Berwanger O, Share D, Schreiber T, Moscucci M, et al. Contemporary use and effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy among patients undergoing percutaneous coronary intervention. JACC Cardiovascular interventions. 2012; 5: 98-104.

148. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, Voudris V. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004; 110: 2837-2842.

149. Alexopoulos E, Spargias K, Kyrzopoulos S, Manginas A, Pavlides G, Voudris V, et al. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media. Am J Med Sci. 2010; 339: 25-30.

150. Boscheri A, Weinbrenner C, Botzek B, Reynen K, Kuhlisch E, Strasser RH. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol. 2007; 68: 279-286.

151. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, et al. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J. 2009; 157: 576-583.

152. Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol. 2013; 62: 2167- 2175.

153. Tasanarong A, Vohakiat A, Hutayanon P, Piyayotai D. New strategy of α- and γ-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrology, dialysis, transplantation. 2013; 28: 337- 344.

154. Kabasakal L, Sehirli AO, Cetinel S, Cikler E, Gedik N, Sener G. Mesna (2-mercaptoethane sulfonate) prevents ischemia/reperfusion induced renal oxidative damage in rats. Life Sci. 2004; 75: 2329- 2340.

155. Ludwig U, Riedel MK, Backes M, Imhof A, Muche R, Keller F. MESNA (sodium 2-mercaptoethanesulfonate) for prevention of contrast medium-induced nephrotoxicity - controlled trial. Clin Nephrol. 2011; 75: 302-308.

156. Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-generation betaadrenergic blocker. Ann Pharmacother. 2006; 40: 1353-1360.

157. Sule SS, Frishman W. Nebivolol: new therapy update. Cardiol Rev. 2006; 14: 259-264.

158. Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahioglu M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant. 2008; 23: 853-859.

159. Avci E, YeÅŸil M, Bayata S, Postaci N, Arikan E, Cirit M. The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction. Anadolu Kardiyol Derg. 2011; 11: 613-617.

160. Günebakmaz O, Kaya MG, Koc F, Akpek M, Kasapkara A, Inanc MT, et al. Does nebivolol prevent contrast-induced nephropathy in humans? Clin Cardiol. 2012; 35: 250-254.

161. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O’Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005; 118: 843- 849.

162. Patti G, Nusca A, Chello M, Pasceri V, D’Ambrosio A, Vetrovec GW, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2008; 101: 279-285.

163. Leoncini M, Toso A, Maioli M, Tropeano F, Bellandi F. Statin treatment before percutaneous cononary intervention. J Thorac Dis. 2013; 5: 335-342.

164. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011; 27: 851-858.

165. Andreucci M. [Statins in CIN: a problem at least partly solved?]. G Ital Nefrol. 2013; 30.

166.